Literature DB >> 2144746

Early serum CA125 response and outcome in epithelial ovarian cancer.

C W Redman1, G R Blackledge, K Kelly, J Powell, E J Buxton, D M Luesley.   

Abstract

The prognostic value of serum CA125 levels before and after two courses of chemotherapy was assessed in 50 patients with advanced epithelial ovarian cancer. Patients with serum CA125 values below 35 U/ml after two courses were significantly more likely to achieve complete remission and had a significantly longer median survival. In multivariate analysis, serum CA125 levels after two courses were the most important independent prognostic factor: it was possible to predict survival status at 12 months with an overall accuracy of 93%. Serum CA125 can be used to evaluate quantitatively chemotherapeutic response and at an early stage classify patients into good and poor risk groups. Such an approach would facilitate the selection of appropriate therapy and could reduce toxicity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2144746     DOI: 10.1016/0277-5379(90)90085-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  The optimal time for surgery in women with serous ovarian cancer.

Authors:  Jocelyn M Stewart; Alicia A Tone; Haiyan Jiang; Marcus Q Bernardini; Sarah Ferguson; Stephane Laframboise; K Joan Murphy; Barry Rosen; Taymaa May
Journal:  Can J Surg       Date:  2016-08       Impact factor: 2.089

2.  Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.

Authors:  Jian-Lun Xu; John Commins; Edward Partridge; Thomas L Riley; Philip C Prorok; Christine C Johnson; Saundra S Buys
Journal:  Gynecol Oncol       Date:  2011-12-22       Impact factor: 5.482

3.  Determination of cancer antigen 125 in ovarian carcinoma.

Authors:  V Thakur; A K Anand; U Mukherjee; D Ghosh
Journal:  Indian J Clin Biochem       Date:  2003-07

4.  CA 125 half-life in ovarian cancer: a multivariate survival analysis.

Authors:  C A Yedema; P Kenemans; F Voorhorst; G Bon; C Schijf; L Beex; A Verstraeten; J Hilgers; J Vermorken
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

5.  An independent evaluation of the potential clinical usefulness of proposed CA-125 indices previously shown to be of prognostic significance in epithelial ovarian cancer.

Authors:  D J Cruickshank; J Paul; C R Lewis; E J McAllister; S B Kaye
Journal:  Br J Cancer       Date:  1992-04       Impact factor: 7.640

6.  CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

Authors:  C Peters-Engl; A Obermair; H Heinzl; P Buxbaum; P Sevelda; M Medl
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

7.  Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature.

Authors:  Digant Gupta; Christopher G Lis
Journal:  J Ovarian Res       Date:  2009-10-09       Impact factor: 4.234

Review 8.  Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer.

Authors:  Shuna Liu; Ming Wu; Fang Wang
Journal:  J Cancer       Date:  2021-05-13       Impact factor: 4.207

9.  The prognostic value of early CA125 serum assay in epithelial ovarian carcinoma.

Authors:  J Fisken; R C Leonard; M Stewart; G J Beattie; C Sturgeon; L Aspinall; J E Roulston
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.